---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096920"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:32:54.016834+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma appoints John Leaman as independent director, formalizes CEO and CFO titles

## Summary
- John Leaman, MD appointed independent director effective Oct 1, 2025; joins Audit Committee.
- Interim titles removed: Iain Dukes now CEO, Charles Parker now CFO of Traws Pharma.
- Dr. Leaman brings experience as CFO of Cellarity, Impel Pharma, Selecta Biosciences.
- Company progressing Phase 2 studies for lead candidate ratutrelvir (COVID-19 treatment).
- CFO Charles Parker compensated via Stout at $500/hr, up to $50k/month for services.

## SEC filing metadata
- accession: 0001104659-25-096920
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/0001104659-25-096920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/tm2528048d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096920
- JSON: https://secwatch.observer/filing/0001104659-25-096920.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.